Who
Peter S. Klein
Director
Company insider
Files Form 4 as: Director, Denali Therapeutics; Director, Accolade; Director, F5; Director, Palladyne AI; Director, Apptio; Chief Financial Officer, Microsoft.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.4M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 30 Aug 2010
- Last trade
- 3 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,226 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,408 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,111 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,037 at $0.00 | filing |
| 8 Apr 2025filed 8 Apr 2025 | Accoladeoption or derivative | SEC FORM 4 Code D | —35,021 | filing |
| 8 Apr 2025filed 8 Apr 2025 | Accoladeoption or derivative | SEC FORM 4 Code D | —20,000 | filing |
| 8 Apr 2025filed 8 Apr 2025 | Accoladeoption or derivative | SEC FORM 4 Code D | —8,600 | filing |
| 8 Apr 2025filed 8 Apr 2025 | Accolade | SEC FORM 4 Code D | $199K28,329 at $7.03 | filing |
| 13 Mar 2025filed 14 Mar 2025 | FFIV F5option or derivative · Software | SEC FORM 4 Code A | —934 at $0.00 | filing |
| 12 Mar 2025filed 14 Mar 2025 | FFIV F5option or derivative · Software | SEC FORM 4 Code M | —1,309 at $0.00 | filing |
| 12 Mar 2025filed 14 Mar 2025 | FFIV F5Software | SEC FORM 4 Code M | —1,309 at $0.00 | filing |
| 5 Sep 2024filed 6 Sep 2024 | FFIV F5Software | SEC FORM 4 Code G | —1,000 at $0.00 | filing |
| 6 Aug 2024filed 8 Aug 2024 | Accoladeoption or derivative | SEC FORM 4 Code A | —35,021 at $0.00 | filing |
| 6 Aug 2024filed 8 Aug 2024 | Accoladeoption or derivative | SEC FORM 4 Code M | —9,196 | filing |
| 6 Aug 2024filed 8 Aug 2024 | Accolade | SEC FORM 4 Code M | —9,196 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,967 at $0.00 | filing |
| 14 Mar 2024filed 15 Mar 2024 | FFIV F5option or derivative · Software | SEC FORM 4 Code A | —1,309 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.